Hainan Lingkang Pharmaceutical Co., Ltd.

It has a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, especially against Escherichia coli, Klebsiella, Haemophilus influenzae, Proteus and Bacteroides fragilis. Its mechanism of action is that it shows a strong affinity for penicillin-binding proteins, which are the usual action points of β-lactam antibiotics. It can inhibit cell wall synthesis and bind to peptidoglycan, inhibiting the binding of peptidoglycan to lipoprotein to promote bacteriolysis, and showing a strong bactericidal effect in a short time. This product shows antibacterial effect on bacteria during the proliferation period and the early stage of the stable period, and has a bactericidal effect at concentrations lower than the MIC, and lyses bacteria in a short time. The antibacterial effect in vivo is stronger than the prediction of the MIC.

Dextrorotatory fructose 1,6-diphosphate (FDP) is an intermediate product of glycolysis. It regulates several enzymatic reactions in cells by activating phosphofructokinase, pyruvate kinase and lactate dehydrogenase. FDP can act on cell membranes, promote the cell's uptake of circulating potassium and stimulate the production of high-energy phosphate and 2,3-diphosphoglycerol in cells. In addition, FDP can reduce hemolysis of erythrocytes caused by mechanical trauma and inhibit the production of oxygen free radicals caused by chemical stimulation. In COPD patients, FDP is beneficial for treatment, especially for strengthening respiratory intensity, which is manifested as an increase in PImax, PaO2 and tolerance.

This product is a monoquaternary ammonium steroid medium-acting non-depolarizing muscle relaxant, similar in structure to pancuronium bromide, which blocks the conduction between nerve endings and striated muscles by competing with acetylcholine for nicotinic receptors located at the motor end plate of striated muscles. Unlike depolarizing neuromuscular blocking drugs such as succinylcholine, this product does not cause muscle fiber bundles to tremble. Intravenous injection of 0.08-0.1mg/kg is effective within 1 minute, reaching a peak in 3-5 minutes, and maintaining for 30-90 minutes. The muscle relaxant effect is 3 times stronger than that of tubocurarine chloride; it has no vagus nerve blocking effect. Since vecuronium bromide does not cause an increase in heart rate, it is suitable for patients with myocardial ischemia and heart disease, but the use of vagus nerve excitants and β-receptor blockers is prone to bradycardia. This product has a weak histamine release effect, and there are also bronchospasm and allergic reactions, but they are rare.

This product is a monoquaternary ammonium steroid medium-acting non-depolarizing muscle relaxant, similar in structure to pancuronium bromide, which blocks the conduction between nerve endings and striated muscles by competing with acetylcholine for nicotinic receptors located at the motor end plate of striated muscles. Unlike depolarizing neuromuscular blocking drugs such as succinylcholine, this product does not cause muscle fiber bundles to tremble. Intravenous injection of 0.08-0.1mg/kg is effective within 1 minute, reaching a peak in 3-5 minutes, and maintaining for 30-90 minutes. The muscle relaxant effect is 3 times stronger than that of tubocurarine chloride; it has no vagus nerve blocking effect. Since vecuronium bromide does not cause an increase in heart rate, it is suitable for patients with myocardial ischemia and heart disease, but the use of vagus nerve excitants and β-receptor blockers is prone to bradycardia. This product has a weak histamine release effect, and there are also bronchospasm and allergic reactions, but they are rare.

This product is a monoquaternary ammonium steroid medium-acting non-depolarizing muscle relaxant, similar in structure to pancuronium bromide, which blocks the conduction between nerve endings and striated muscles by competing with acetylcholine for nicotinic receptors located at the motor end plate of striated muscles. Unlike depolarizing neuromuscular blocking drugs such as succinylcholine, this product does not cause muscle fiber bundles to tremble. Intravenous injection of 0.08-0.1mg/kg is effective within 1 minute, reaching a peak in 3-5 minutes, and maintaining for 30-90 minutes. The muscle relaxant effect is 3 times stronger than that of tubocurarine chloride; it has no vagus nerve blocking effect. Since vecuronium bromide does not cause an increase in heart rate, it is suitable for patients with myocardial ischemia and heart disease, but the use of vagus nerve excitants and β-receptor blockers is prone to bradycardia. This product has a weak histamine release effect, and there are also bronchospasm and allergic reactions, but they are rare.